Minova Life Science

Minova life sciences - Pharmaceutical company

Teslio M-500 Tablets

COMPOSITION РSitagliptin phosphate IP 50 mg& Metformin  HCI 500 mg


Sitagliptin (DPP-4 inhibitor)

  • ¬†Approved by the US Food and Drug Administration (FDA) for use with diet and exercise to Improve glycemic control in adult patients with type 2 diabetes,
  • Sitagliptin is a highly selective DPP-4 inhibitor that has been approved for type 2 diabetes therapy. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion.


  • It is a biguanide that decreases blood glucose concentration by mechanisms different from those of insulin secretagogues, such as sulfonylurea, or exogenous insulin therapy.
  • Unlike the sulphonylureas, metformin does not cause hypoglycemia, it is an effective antihyperglycemic agent which appears to improve aberrant plasma lipid and fibrinolytic profiles associated with non-insulin-dependent diabetes mellitus.

Explore other products

Scroll to Top